Study of Therapeutic to Restore Hearing Aims to Show Speech Perception Improvements in Individuals with Noise-Induced or Permanent Sudden Sensorineural Hearing Loss
Company Aligned with FDA on Speech Perception Primary Endpoint
Readout Expected in Q1 2023
LEXINGTON, Mass., October 12, 2022--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a persons innate potential to restore function, today announced that it has completed enrollment of its placebo-controlled Phase 2b study of FX-322 in adults with acquired sensorineural hearing loss (SNHL). The FX-322-208 study, which enrolled 142 individuals, is designed to show improvement in a pre-specified measure of speech perception. The Company plans to release study data in the first quarter of 2023.
"I am very pleased with our teams execution of this study for the first potential treatment to restore hearing for those with SNHL. The 208 study was rigorously designed to ensure the stability of an individuals hearing prior to entering the trial and to exclusively enroll those with the types hearing loss where we observed the strongest hearing improvement in prior FX-322 studies. FX-322 continues to have a favorable safety profile and we are aligned with FDA on the primary speech perception endpoint. With a successful outcome of this single-dose study, our intent is to advance the program into Phase 3 trials," said David L. Lucchino, Frequencys chief executive officer.
Mr. Lucchino continued: "We are grateful to all the study volunteers, clinicians and site staff for their time and commitment to this trial. We believe the high level of interest from patients and healthcare providers in this study further demonstrates the need for a novel, disease modifying hearing loss treatment to expand the standard of care for the millions of individuals with sensorineural hearing loss."
Story continues
FX-322-208 Study Design
FX-322-208 is a prospective, randomized, double-blinded, placebo-controlled, multi-center Phase 2b study designed to evaluate the efficacy of a single administration of FX-322 on speech perception in subjects aged 18-65 with hearing loss associated with either noise-induced or permanent idiopathic sudden SNHL. The study enrolled 142 participants, exceeding the original enrollment target of approximately 124, and is being conducted at 28 clinical sites across the US.
The Company previously aligned with the US Food and Drug Administration (FDA) on the use of the specific speech perception primary endpoint. With improved speech perception, individuals may hear words more clearly, a critical unmet need for individuals with hearing loss. The FX-322-208 study is powered at 80% (significance level of 0.05) to observe a statistically significant and clinically meaningful improvement in speech perception at day 90 following dosing, with study responders defined as individuals exceeding the upper 95% confidence interval in the speech perception test. The Company has not publicly disclosed the specific test used for the primary endpoint to maximize the rigor of the study and mitigate potential bias.
During the study, subjects participate in a range of audiologic exams, including pure-tone audiometry, word recognition in quiet, word recognition in noise, the Tinnitus Functional Index (TFI), as well as multiple patient-reported outcome measures including Frequencys proprietary patient reported outcome instrument (RADIAL) in acquired SNHL. All subjects are required to have a documented audiogram from at least six months prior to screening and most patients are evaluated over a 270-day period following dosing. The studys rigorous design includes a lead-in phase with multiple baseline measures. Subjects with instability of baseline tests are disqualified from participation in the study. Study audiometry testing sessions are recorded and monitored by third party audiologists to ensure consistency and identify any anomalies related to how tests were conducted.
In prior studies, the Company observed the greatest concentration of speech perception improvements in individuals with permanent sudden or noise-induced sensorineural hearing loss in the moderate to lower severe hearing loss range. These learnings informed the design and inclusion criteria for the FX-322-208 study. More than 200 individuals have been dosed with a single injection of FX-322 in prior or ongoing studies, and the drug candidate has continued to exhibit a favorable safety profile with no drug-related serious adverse events.
About Sensorineural Hearing Loss
Sensorineural hearing loss is the most common form of hearing loss, typically resulting from damage to sensory hair cells in the cochlea. These cells convert sound waves to signals sent to the brain which are interpreted as speech and sound. Sensory hair cells are lost due to chronic noise exposure, aging, certain viral infections or exposure to drugs that are toxic to the ear. This type of hearing loss impacts around 40 million individuals in the U.S. alone.
About Frequency Therapeutics
Frequency Therapeutics is leading a new category in regenerative medicine that aims to restore human function first in hearing loss and then in multiple sclerosis by developing therapeutics that activate a persons innate regenerative potential within the body through the activation of progenitor cells. Frequencys hearing research focuses on cochlear restoration and auditory repair, and its lead asset, FX-322, is a small-molecule combination product candidate that is the first to show statistically significant and clinically meaningful hearing improvements in clinical trials for sensorineural hearing loss. Frequency is also following early restorative signals in MS to develop medicines with the same underlying regenerative science being brought to hearing loss.
Headquartered in Lexington, Mass., Frequency has an ex-U.S. license and collaboration agreement with Astellas Pharma Inc. for FX-322, as well as additional collaboration and licensing agreements with academic and nonprofit research organizations including Massachusetts Eye and Ear, Mass General Brigham, the Massachusetts Institute of Technology, and the Scripps Research Institute.
For more information, visit http://www.frequencytx.com and follow Frequency on Twitter @Frequencytx.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the timing and design of the Phase 2b study (FX-322-208), including the timing of results and the ability of design features to reduce bias, the commencement of any future FX-322 trials, the interpretation and implications of the results and learnings of other FX-322 clinical studies, the treatment potential of FX-322, estimates of the size of the hearing loss population, the acceptance by the FDA of particular endpoints in the Companys trials, and the potential application of the progenitor cell activation (PCA) platform to other diseases.
These forward-looking statements are based on managements current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the impact of COVID-19 on the Companys ongoing and planned clinical trials, research and development and manufacturing activities, the Companys business and financial markets; the Company has incurred and will continue to incur significant losses and is not and may never be profitable; the Companys need for additional funding to complete development and commercialization of any product candidate; the Companys dependence on the development of FX-322; the unproven approach of the PCA platform and the inability to identify additional potential product candidates; the lengthy, expensive and uncertain process of clinical drug development and regulatory approval; the Companys limited experience successfully obtaining marketing approval for and commercializing product candidates; the results of earlier clinical trials not being indicative of the results from later clinical trials; differences between preliminary or interim data and final data; adverse events or undesirable side effects; disruptions at the FDA and other regulatory agencies; failure to identify additional product candidates; new or changed legislation; failure to maintain Fast Track designation for FX-322 and such designation failing to result in faster development or regulatory review or approval; ability to seek and receive Breakthrough Therapy designation for FX-322; the Companys ability to enroll and retain patients in clinical trials; costly and damaging litigation, including related to product liability or intellectual property or brought by stockholders; dependence on Astellas Pharma Inc. for the development and commercialization of FX-322 outside of the United States; misconduct by employees or independent contractors; reliance on third parties, including to conduct clinical trials and manufacture product candidates; compliance with changing laws and regulations, including healthcare and environmental, health, data privacy and safety laws and regulations; failure to obtain, maintain and enforce protection of patents and other intellectual property rights covering product candidates; security breaches or failure to protect private personal information; attracting and retaining key personnel; and the Companys ability to manage growth.
These and other important factors discussed under the caption "Risk factors" in the Companys Form 10-Q filed with the Securities and Exchange Commission (SEC) on August 9, 2022 and its other reports filed with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent managements estimates as of the date of this press release. While the Company may elect to update such forward-looking statements at some point in the future, it disclaims any obligation to do so, even if subsequent events cause its views to change. These forward-looking statements should not be relied upon as representing the Companys views as of any date subsequent to the date of this press release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221012005144/en/
Contacts
Investor:Carlo Tanzi, Ph.D.Kendall Investor Relationsctanzi@kendallir.com 617-914-0008
Media:Frequency TherapeuticsEmail: media@frequencytx.com
See original here:
Frequency Therapeutics Completes Enrollment of Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss - Yahoo Finance
- Regenerative medicine UKRI - UK Research and Innovation - December 10th, 2023
- What Is Regenerative Medicine? | Goals and Applications | ISCRM - December 2nd, 2023
- What Is Regenerative Medicine? | Mass General Brigham - December 2nd, 2023
- Advancing Safe and Effective Regenerative Medicine Products - March 20th, 2023
- Can This Companys Research Help Transform Regenerative Medicine As Its ... - December 18th, 2022
- Regenerative Medicine in Pharma Market Size, Share and Trends Analysis by Region, Drug Class, Route of Administration, and Segment Forecast, 2022-2027... - December 10th, 2022
- Stem Cells Applications in Regenerative Medicine and Disease ... - November 16th, 2022
- Neuroregeneration - Center for Regenerative Biotherapeutics - Mayo ... - November 16th, 2022
- Journal of Immunology and Regenerative Medicine - ScienceDirect - November 16th, 2022
- A Look At Some Of The Companies Innovating In the Cutting-Edge ... - November 16th, 2022
- Regenerative Medicine Advanced Therapy Designation | FDA - October 29th, 2022
- Packing More Punch for Regenerative Medicine and Cell and Gene Therapies - Inside Precision Medicine - October 29th, 2022
- Brush Up: Tissue Engineering and Regenerative Medicine - The Scientist - October 21st, 2022
- The Alliance for Regenerative Medicine Announces Election of 2023 Officers, Executive Committee, and Board of Directors - GlobeNewswire - October 13th, 2022
- Husband and Wife Team Bring Regenerative Medicine Clinic to Jackson - Franchising.com - October 13th, 2022
- Hundreds run for regenerative medicine research at the 2022 TCS London Marathon - British Heart Foundation - October 13th, 2022
- SANUWAVE's Energy First Technology to be Featured in 3 Clinical Posters at Upcoming 2022 Fall Symposium on Advanced Wound Care (SAWC) -... - October 13th, 2022
- 3D Bioprinting Market Size to Touch Valuation of $1.5 Billion by 2028 | Inkjet Technology Generates More than 38% Revenue of Bioprinting Market -... - October 13th, 2022
- QC Kinetix (Columbia) Offers Regenerative Medicine Treatments to Treat Different Types of Physical Pain and Injuries - Yahoo Finance - October 4th, 2022
- Astellas and Pantherna Enter into a New Technology Evaluation Agreement for Research with Expanded Target Organ to Generate mRNA-Based Regenerative... - October 4th, 2022
- Company / An Advance In Vaginal Rejuvenation, Regenerative Medicine And Aesthetic Gynecology - World Nation News - October 4th, 2022
- Performance Rehabilitation and Regenerative Medicine's Dr. Joseph Mejia honored as a Castle Connolly Top Doctor - Jersey's Best - October 4th, 2022
- Teijin, J-TEC, Mitsui Fudosan, and NCC to create a new platform for regenerative medicine innovation - The Worldfolio - October 4th, 2022
- Cell Regeneration Medicine Market to be valued at US$ 34.3 Bn by the end of 2022 | FMI Research - PharmiWeb.com - October 4th, 2022
- Enlivex to Present at the 4th Macrophage-Directed Therapies Summit - Yahoo Finance - October 4th, 2022
- Fracturing bones and traditional views of civil engineering - ASU News Now - October 4th, 2022
- BioMarin Resubmits Biologics License Application (BLA) for Valoctocogene Roxaparvovec AAV Gene Therapy for Severe Hemophilia A to the FDA - PR... - October 4th, 2022
- Organ on a Chip Market - Focus on Products and Technologies - Distribution by Type of Product, Application Area, Purpose, and Key Geographical Regions... - October 4th, 2022
- QC Kinetix (Riverside Parkway) Offers Regenerative Medicine Treatments to Treat Pain and Injuries in Tulsa, OK - Yahoo Finance - September 25th, 2022
- Reprogramming pig cells leads way for new regenerative therapies - National Hog Farmer - September 25th, 2022
- Research Roundup: Regenerative Potential, Long COVID Insights, Immuno-Oncology and More - BioSpace - September 25th, 2022
- Dr. Batcheller's Wellness and Esthetics, Mecca for Regenerative Medicine and Esthetics - Digital Journal - September 25th, 2022
- Organicell Regenerative Medicine, Inc. Announces Expansion of Management Team - Yahoo Finance - September 25th, 2022
- Pfizer and Sangamo Therapeutics Announce Phase 3 Trial of Investigational Gene Therapy for Hemophilia A Has Re-Opened Recruitment - Pfizer - September 25th, 2022
- Neurona Therapeutics Presents Clinical Case Study from First Human Trial of Regenerative Cell Therapy, NRTX-1001, in Adults with Drug-Resistant Focal... - September 25th, 2022
- Center for Breakthrough Medicines (CBM) and jCyte Announce Strategic Partnership to Manufacture jCyte's Innovative Cell Therapy for Treatment of... - September 25th, 2022
- 2022 UK Equine Research Hall of Fame Inductees Announced The Horse - TheHorse.com - September 25th, 2022
- Science on the go: Catch the Veterinary Vertex podcast - American Veterinary Medical Association - September 25th, 2022
- Advanced robotics to address the translational gap in tendon engineering - EurekAlert - September 25th, 2022
- Russ Olsen Makes Multi-Million Dollar Pledge in support of the Robert Morris University Library - Robert Morris University - September 25th, 2022
- Humacyte Expands Board of Directors and Leadership Team with New Appointments - Yahoo Finance - September 25th, 2022
- First time in India: Stem cell therapy to treat knee osteoarthritis - Moneycontrol - September 25th, 2022
- George Church: Learn from COVID and fast-track therapies that reverse aging - Longevity.Technology - September 25th, 2022
- EpiBone CEO and Co-Founder Dr. Nina Tandon Selected to Participate in White House Summit - PR Web - September 25th, 2022
- Krystal Biotech Receives Positive Opinion from EMA Pediatric Committee on the Pediatric Investigation Plan for B-VEC for the treatment of Dystrophic... - September 25th, 2022
- Humacyte Announces Presentations by Ukrainian Surgeons on Use of the Human Acellular Vessel to Treat Wartime Vascular Trauma at the European Society... - September 25th, 2022
- Fertility Supplements And Vitamins For Women: What You Need To Know - Forbes - September 25th, 2022
- CIRM awards UCI $2.7 million to create regenerative medicine training program - UCI News - September 16th, 2022
- Regenerative Medicine Hub at W-S Innovation Quarter keeps growing with new addition - WRAL TechWire - September 16th, 2022
- QC Kinetix (Chandler): The Future of Regenerative Medicine in Arizona - Digital Journal - September 16th, 2022
- Platelet-Rich Plasma: A Promising Regenerative Therapy in Gynecological Disorders - Cureus - September 16th, 2022
- 4 to be inducted into UK Equine Research Hall of Fame - WTVQ - September 16th, 2022
- FACT SHEET: The United States Announces New Investments and Resources to Advance President Bidens National Biotechnology and Biomanufacturing... - September 16th, 2022
- AVITA Medical Achieves Positive Topline Pivotal Trial Results for Treatment of Stable Vitiligo Using the RECELL System - Yahoo Finance - September 16th, 2022
- Cell Culture Media Market worth $10.3 billion by 2026 - Exclusive Report by MarketsandMarkets - GlobeNewswire - September 16th, 2022
- Following some big FDA wins, Carmell Therapeutics plans to go public. Here's why - Technical.ly - September 16th, 2022
- Pharmaceutical Drug Delivery Market is expected to generate a revenue of USD 2,583 Billion by 2030, Globally, at 6.6% CAGR: Verified Market Research -... - September 16th, 2022
- Capstan Therapeutics Launches with $165 Million to Deliver on the Clinical Promise of Precise In Vivo Cell Engineering - Business Wire - September 16th, 2022
- Children's Health will fund pediatric unit at the Texas Health and Human Services Commission UT Southwestern Medical Center psychiatric hospital - UT... - September 16th, 2022
- Cell Line Development Market Projected to Experience a CAGR of 5% from 2022 to 2032, value worth US$ 7.66 Billion | Future Market Insights, Inc. -... - September 16th, 2022
- UB researchers identify new model of cerebral cortex development linked to reelin protein expression - EurekAlert - September 16th, 2022
- NYC Dermatologist, Dr. Julie Russak, launches first Anti-Aging Wellness Program of its kind in the U.S. - PR Web - September 16th, 2022
- About Regenerative Medicine - Center for Regenerative Biotherapeutics ... - September 8th, 2022
- Global Exosome Market Report 2022: Integration into Fields of Liquid Biopsy, Precision Medicine, and Regenerative Medicine Driving Growth -... - September 8th, 2022
- Addressing Diversity Barriers to Regenerative Medicine Free Press of Jacksonville - Jacksonville Free Press - September 8th, 2022
- Looking to buy Mesoblast shares? Here's the latest on where the ASX biotech is at with the FDA - The Motley Fool Australia - September 8th, 2022
- Sernova Announces the Appointment of Daniel Mahony, Ph.D. to its Board of Directors - GlobeNewswire - September 8th, 2022
- 7.5 Million Granted to Collaborative PROTO Project led by Charit to Study Pluri's PLX-PAD Cells for Osteoarthritis Treatment - GlobeNewswire - September 8th, 2022
- Regenerative Medicine Market to Garner Bursting Revenues [+USD 27.29 Billion] with Top Growing Companies During 2022-2029 - eTurboNews | eTN - August 30th, 2022
- ElevateBio Partners with the California Institute for Regenerative Medicine to Accelerate the Development of Regenerative Medicines - Business Wire - August 30th, 2022
- Global Cell Therapy Market to Reach a Capital Expenditure of USD 10.23 billion in 2021 - eTurboNews | eTN - August 30th, 2022
- Therapeutic Solutions International Develops Gene Silencing Therapy for Acute Respiratory Distress Syndrome - BioSpace - August 30th, 2022
- How Astrocytes May Be Able to Help With Brain Repair - Best Health Magazine - August 30th, 2022
- Applied StemCell Announces the Expansion of its cGMP Manufacturing Facility to Support Cell and Gene Therapy - Business Wire - August 30th, 2022
- Scientists just bypassed millions of years worth of evolution in mice - Inverse - August 30th, 2022
- NIAMS Update, Issue 4, 2022 | NIAMS - National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) - August 30th, 2022
- Heart Association fellowship to support research - Binghamton - August 30th, 2022
- Climate change is making the new school year harder in all kinds of ways - Salon - August 30th, 2022
- Global Biomaterials Market to Reach Value of $372.7 Billion by 2028 | Demand For Biomaterials in the Healthcare Industry will Grow by 53% Over the... - August 30th, 2022
- Dosing of Novel Autologous CAR T Cells and Nivolumab Begins in cHL Study - Targeted Oncology - August 22nd, 2022